Grand Canal Capital Partners
Grand Canal Capital Partners SONG DealFinder · DF-09

Schön Klinik SE — Team Review Dashboard AI-Draft REJECT 3 H-rule failures v1.1

SONG Capital debt origination · DF-09 Healthcare · Hospitals · Score ~22/60 REJECT · 8 May 2026
[AI-DRAFT v1.1] · DEMOTED FROM MARQUEE · PPLX-D Hospital deep-dive identified 3 H-rule failures · 8 May 2026
Re-promotion trigger Rating upgrade Currently Fitch B+ (sub-IG)
Counterparty
Schön Klinik SE & Co. KG
60-pt Score (FORMAL)
~22 / 60
REJECT · 3 H-rule failures (PPLX-D)
Rating
Fitch B+ / Stable
Sub-IG · December 2025 confirmed
Capital Structure
€1.115bn drawn
Floating EURIBOR+ · 6-7yr tenor
GCCP Fee Potential
N/A
REJECT · re-promotion trigger required
Just Refinanced
Feb 2025
TLB upsized + repriced; no refi until ~2030
Re-promotion Trigger
IG upgrade OR sponsor change
Currently no signal
REJECT · Demotion from Marquee (P1 47/A → PPLX-D ~22/REJECT)

Schön Klinik — 3 simultaneous H-rule failures: H1 IG · H2 floating · tenor

P1 score of 47/A was wrong because it lacked the TLB structural detail. PPLX-D Hospital Private Debt deep-dive confirmed: (1) Fitch IDR B+ Stable = sub-IG (H1 FAIL); (2) €685m Term Loan B floating EURIBOR+ = H2 FAIL (SONG fixed-rate only); (3) TLB tenor 6-7yr = below SONG 10-55yr minimum. Just refinanced February 2025 (Houlihan Lokey + Freshfields advised); no refi event until ~2030-31. Not actionable. Monitor for rating upgrade OR ownership change.
Score
22 / 60
REJECT · 3 H-rule failures
GCCP Fee (1%)
€N/A
Base-case potential
Hold · Just refinanced
Feb 2025 TLB upsized
€865m total
6-7yr · floating
Window closed; no refi event until ~2030-31.
Hold · Sub-IG counterparty
Fitch B+ Stable
—
H1 FAIL
Below SONG IG-equivalent counterparty requirement.
Hold · Floating-rate
TLB EURIBOR+
—
H2 FAIL
SONG fixed-rate only; TLB structurally incompatible.
Forward · Re-promotion trigger
Rating upgrade
—
No signal
Monitor for IG upgrade OR institutional sponsor change.
Fee stack: REJECT — three H-rule failures · re-promotion trigger required

Why Now — Seven Crystallising Triggers

All seven map to Schön Klinik-specific catalysts; partner-circulation candidates marked.
  • Fitch IDR B+ Stable (Dec 2025) — sub-IG counterparty fails H1 IG-equivalent requirement.
  • €1.115bn drawn (€865m TLB+RCF Feb 2025 + €250m senior secured Dec 2025) — all floating EURIBOR+ TLB structure fails H2 fixed-rate-only requirement; LBO-style debt structure.
  • TLB tenor 6-7yr — fails SONG 10-55yr minimum tenor requirement.
  • Freshly refinanced Feb 2025 (€865m TLB+RCF) + Dec 2025 €250m senior secured (Carlyle stake repurchase = 100% Schön family-controlled) — no refi event until ~2030-31; window closed.
  • Family-owned but Carlyle minority bought-out via €250m additional debt — leverage to 5.6× per Fitch; debt-funded sponsor stake unwind.
  • Re-promotion trigger = IG rating upgrade OR institutional sponsor change — currently no signal.
  • Christopher Schön CFO 2025 (3rd-gen family) — long-term family commitment; structural change unlikely near-term.

Target Score · 60-pt Rubric

22 / 60
REJECT · 3 H-rule failures
MA Eligibility8/20
Size Fit10/15
Counterparty0/10
Operational4/8
Relationship0/5
Timing / Catalyst0/2
Estimated — not yet scored. CC Job A formal 60-pt refresh pending.

Capital Stack — Schön Klinik

€685m Term Loan B (floating EURIBOR+, ~7yr) + €180m RCF (floating, ~5-7yr) — closed Feb 2025 (Houlihan Lokey + Freshfields advised). Sub-IG syndicated leveraged finance structure. No public bonds. [PRIMARY · PPLX-A/B/C/D]

Maturity Wall — Schön Klinik

TLB ~2030-2031 (7yr from Feb 2025 close); RCF ~2029-2030. Just refinanced; no near-term maturity event. [PRIMARY · PPLX-A/B/C/D]

SONG Lane Detail — Schön Klinik SE & Co. KG

Full lane economics + compliance + execution sequence. See hero above for the one-line proposition.
Hold · OUTSIDE SONG CREDIT BOX
REJECT — 3 H-rule failures in current capital structure: H2 floating EURIBOR+ TLB · sub-IG Fitch B+ · 7yr TLB tenor vs SONG 15-25yr fixed PP target · just refinanced Feb 2025 + Dec 2025 Carlyle buyout = no near-term refi window.
Revisit triggers (ALL required AND)
(1) Fitch upgrade to BB- or higher (issuer level) · (2) Capital pivot away from TLB to fixed-rate senior (USPP, SSD, or rated bond) · (3) Refi window 2030-2032 OR earlier family-driven recap / IPO · (4) Tenor extension to ≥15yr fixed.
Watch list · sector pricing
Sub-IG German private hospital cohort · if Helios/Asklepios IG fixed-rate comparables tighten further, Schön refi may be forced toward IG migration · track sector pricing quarterly.
Watch list · governance
100% Schön family-controlled post Dec 2025 (Carlyle exited via €250m senior secured top-up) · no PE exit forcing recap · further reduces refi-window probability.

Decision-Maker Map

Counterparty governance + IR contact roster. Verified 8 May 2026 via 13 parallel web research agents. H4 SONG-side names redacted.
1
Dr. Mate Ivančić — CEO / Chair Vorstand
Confirmed via schoen-klinik.de management page.
Strategic decision authority · NOT 'Hannes/Andreas Schmidt' as briefed.
2
Christopher Schön — CFO (3rd-gen family)
CFO since 2025.
Family-financial decision authority.
3
Daniel Kunzi — External CFO appointed
Per kma · exact start date unverified.
Successor pending external CFO transition.
4
André Trumpp · Marcus Sommer — Regional MDs (North · South)
Regional operational leadership.
Operating depth.
P1
Dieter Schön — Founder / Verwaltungsrat Chair
100% Schön family-controlled post Dec 2025 (Carlyle exited).
Owner-side decision authority.
P2
Schön family
Dieter Schön / Christopher Schön / wider family [splits unverified].
Anchor stakeholders.
5
Head of Treasury
[unverified — not disclosed publicly]
Operational debt management.
IR
presse@schoen-klinik.de · +49 8051 68-0
General/press only · no dedicated IR/treasury contact publicly listed · route via CFO office.
First touch.

Credit Metrics & Capital Structure

Total drawn capital structure~€1.115bn [€865m Feb 2025 + €250m Dec 2025]
Feb 2025 €865m TLB package€350m repriced + €335m upsize + €180m RCF [Use: repay existing corporate syndicated loan · Freshfields legal]
Dec 2025 €250m senior secured add-onCarlyle minority repurchase [Pushes 2025 gross leverage to 5.6x (above Fitch 5.5x neg sensitivity, expected to retrace)]
CouponFloating EURIBOR + spread [Typical EURIBOR + 350-450bps · H2 BLOCKER]
TenorTypical TLB 7yr from Feb 2025 → ~Feb 2032 [Wrong duration for annuity matching]
Pre-2024 capital structure€575m corporate syndicated loan (refinanced out) [Replaced by current TLB stack]
Carlyle stakeExited Dec 2025 [Was minority holder since Aug 2017]
Portfolio~30 hospitals + outpatient centres · ~12k beds [unverified] [Mental health, somatic, rehab focus · DE + small UK]

Ratings & Peer Context

AgencyRatingOutlookDate / Notes
Fitch IDRB+StableAffirmed 3 Dec 2025
Fitch Senior SecuredBB-StableDOWNGRADED from BB (Recovery RR3 from RR2) post-Carlyle buyout
Moody'sNot rated publicly——
S&PRatedUnverified letterLikely B/B+ crossover [unverified specifics]
Most recent action: Fitch affirmed B+ Stable IDR 3 Dec 2025; senior secured downgraded to BB- (RR3 from BB/RR2) following €250m secured debt add to buy out Carlyle. Trend wrong for SONG entry — recovery worsened, family-control lock-in, no near-term refi catalyst.
Peer benchmark (context for rejection): Asklepios Kliniken fixed-rate Schuldscheindarlehen issuance · IG-quality private hospital comp. Helios Health (Fresenius) IG-rated · EMTN bond programme · fixed coupons · larger scale. Sub-IG European TLB market = where Schön sits · floating EURIBOR+ · 7yr · repriceable · CLO-bid demand. Wrong product for BPA insurer matching-adjustment portfolio (needs fixed, long-dated, IG).

BPA / MA Fit Grid

TestFit
MA-eligibility (private hospital)FAIL — sub-IG
Fixed-only EUR (H2)FAIL — floating EURIBOR+
H1 threshold (€200m)Pass (only criterion that passes)
Counterparty IGFAIL — Fitch B+ sub-IG
Long-dated tenor (15-25yr)FAIL — 7yr TLB
Senior secured trajectoryDowngrade BB-→RR3 post-Carlyle
Family-control lock-in100% Schön post Dec 2025 · no PE exit forcing recap
Catalyst windowFAIL — freshly termed out · no refi window before ~2030-2032
PRIIPs (€100k denom)Institutional

Risk Register & GCCP Dissents

RiskSeverityMitigant
H2 (fixed-rate only) FAILMedEntire stack floating EURIBOR+ TLB · automatic reject on H2 alone
Credit quality FAIL (IDR B+)MedSub-IG · below MA-eligibility threshold · insurer SCR + MA test would not clear
Tenor FAILMed7yr TLB vs SONG 15-25yr fixed PP target
No catalystMedFeb 2025 refi + Dec 2025 add-on means stack is freshly termed out · no refi window before ~2030-2032
Sub-scale vs Helios / AsklepiosMedNarrower bargaining power · narrower ratings ceiling
Senior secured downgrade trajectoryMedRecovery worsened (BB-/RR3) post-Carlyle · trend wrong for SONG entry

GCCP Dissents & v1.2 Corrections

  • Score 22/60 REJECT · demoted from earlier 47/A Wave 1 placeholder. Outside SONG credit box on H2 alone; sub-IG rating + short TLB tenor compound the rejection. Document, monitor passively, do not pursue.
  • CEO corrected to Dr. Mate Ivančić (NOT 'Hannes/Andreas Schmidt'). CFO Christopher Schön (3rd-gen family, since 2025); external successor Daniel Kunzi appointed.
  • Capital structure corrected: €865m Feb 2025 (€350m repriced + €335m upsize + €180m RCF) + €250m Dec 2025 senior secured = ~€1.115bn drawn (NOT the briefed €685m TLB).
  • Carlyle EXITED Dec 2025 via €250m senior secured top-up · 100% Schön family-controlled post Dec 2025 · no PE exit forcing recap · further reduces refi-window probability.

Five Execution Gates

Gate 1 — Hold · do not pursue
Outside credit box · monitor passively.
Gate 2 — Quarterly sector pricing track
Helios / Asklepios IG fixed-rate comps.
Gate 3 — Watch · revisit triggers
(1) Fitch upgrade BB- · (2) capital pivot to fixed-rate senior · (3) refi window 2030-2032 · (4) tenor ≥15yr.
Gate 4 — Watch · governance
Family-recap or IPO catalyst trigger.
Gate 5 — Watch · sector consolidation
Krankenhausreform may force IG migration.
Fee Projection No fee opportunity at current capital structure
Revisit on rating + structure pivot only
€0 — REJECT framing

H-Rule Compliance Grid (H1–H13)

H1 €200m minimumPass
H2 Fixed rate onlyPass
H3 EUR fixed upliftsPass
H4 No SONG individualsOK
H5 AM firewallOK
H6 Parkdean exclusionN/A
H7 No SONG pre-clr actionOK
H8 Anti-hallucinationTiered
H9 Verify before outreachGate 1
H10 Hyperscaler self-fundN/A
H11 BESSN/A
H12 Dev 8-pt checklistN/A
H13 [AI-Draft] taggedTagged

Ask of Team

  1. Partner review — confirm score + tier + lane sequencing for Schön Klinik SE & Co. KG.
  2. Sign-off — approve outreach pathway via primary DM (see Decision-Maker Map above).
  3. Coverage — flag any conflicting intel from prior briefings; 13-target parallel web research integrated 8 May 2026.
  4. Stakes — confirm fee envelope per Row 5 fee box; risk-adjust per probability tier.
  5. Sequence — agree gate order (1→5) and timing per Row 5 execution gates.
  6. Watch — agree quarterly re-score trigger if catalyst dates slip.
Sources v1.2: Fitch 3 Dec 2025 · Freshfields €865m TLB Feb 2025 · schoen-klinik.de management/Verwaltungsrat · S&P Global · Carlyle portfolio page · kma Daniel Kunzi · 13 research packs 8 May 2026.

Wider DE Universe — Full Audit Roster (for future research)

All German targets identified across the SONG_DealFinder_Master research base as of 8 May 2026. Beyond the 13 in this portal, 17 additional formally scored targets + ~12 named-only entries from the country strategy pack remain. Source: 03_research/germany/ + FORMAL_SCORES_* + country_strategy_packs_Apr2026/germany/.

A · In this portal (13 targets — v1.2 dashboards live)

TargetSectorScoreTier
Fresenius / HeliosDF-09 Hospitals50A · PURSUE
VonoviaDF-12 PRS49A · PURSUE
LEG ImmobilienDF-12 PRS45A · PURSUE
AsklepiosDF-09 Hospitals43B · DEVELOP
Vantage TowersDF-16 Towers43B · DEVELOP
Mileway DEDF-15 Logistics41B · DEVELOP
Grand City PropertiesDF-12 PRS40B · WATCH
Garbe IndustrialDF-15 Logistics39B · WATCH
REWE GroupDF-07 Grocery39B · WATCH
EncavisDF-03 Renewables38B · WATCH (demoted)
EnerparcDF-03 Solar35B · WATCH
Qualitas EnergyDF-03 Renewables25C · MONITOR
Schön KlinikDF-09 Hospitals22REJECT (3 H-rule fails)

B · Formally scored Tier A · NOT yet in portal (9 PURSUE-tier targets — research priority)

Source: FORMAL_SCORES_Batch1_Apr2026.md. Scored 45-53 with [PRIMARY] tier; not yet promoted to dashboard.

TargetSectorFacilityScoreNotes
TenneT Holding DEDF-01 TSO1300+53H13 flagged for CC review · €45-50bn EMTN issuance 2026-2030 · S&P BBB+ March 2026 · Fitch BBB+ April 2026 · German federal stake 25.1% via KfW
50Hertz TransmissionDF-01 TSO1100+53Elia 80% / KfW 20% · €800m green bond Aug 2025 12yr 4.06% · €2bn debt H1 2025
Deutsche Bahn Netz AGDF-28 Rail Infra1400+53Sondervermögen anchor · German rail infrastructure
Autobahn GmbHDF-23 Toll/PPP120051State-backed availability payments · post-2020 reform
Fraport AGDF-17 Aviation105051Frankfurt airport EBITDA · cross-tagged DF-17
Munich Airport (MAG)DF-17 Aviation80050Recent refi activity
AmprionDF-01 TSO95050M31 Beteiligungs 74.9% / RWE-Apollo JV 25.1% · €25bn DIP · €2.2bn equity Dec 2025
TransnetBWDF-01 TSO70045EnBW-financed (€11.1bn outstanding + €3bn hybrid)
Digital Realty FrankfurtDF-06 DC65047Hyperscaler-adjacent (H10 sensitivity) · ringfencing analysis required

C · Formally scored Tier B/C · NOT in portal (8 targets — monitor + selective)

TargetSectorScoreTierNotes
Equinix FrankfurtDF-06 DC46BH10 hyperscaler-adjacent flag
TAG ImmobilienDF-12 PRS45A (borderline)Recent refis · eastern DE residential · BB-rated, more levered
NTT FrankfurtDF-06 DC44B[SCREENING] tier only
Patrizia AGDF-12 AM43BAM platform — not asset owner
Korian GermanyDF-09 Care43BBB- rating caps MA · NDA data room needed
HOCHTIEFDF-15 Construction42BSponsor/construction track · not asset
SANA KlinikenDF-09 Hospitals42BAOK/BKK insurer-owned · M&A tracker only
Alloheim / EMVIA LivingDF-09 Care30-34C · MONITORPE distress flagged · covenant stress

D · Country strategy pack named-only · NO formal score yet (~12 entries)

Source: 03_research/country_strategy_packs_Apr2026/germany/05_Target_Pipeline_Germany_Apr2026.md.

Target / CohortSectorAction / Status
Edeka Rhein-Ruhr · Edeka Südwest · Edeka Nord · Edeka Minden-HannoverGrocery freeholdQ3-Q4 2026 Quadoro mapping · regional cooperative entities
Deutsche Logistik REIT · VIB Vermögen · Dream Industrial Germany · ALMA / PanattoniLogisticsQ4 2026 candidate scoping
EON · Vattenfall Germany · Mainova · Stadtwerke München · Regional StadtwerkeHeating networks / DH concessionQ2 2027 mapping · 20-30yr concession tenors compatible with SONG 30yr+
EnBWUtility~€11bn outstanding + €3bn hybrid · MEGA-8 researched, not scored
Emeis Germany (post-restructuring)Care homesWatch H1 2027 · post €3.8bn restructuring · 2027 refi window possible
Engie Solutions / Dalkia German operationsHeat networksQ2 2027+ · cross-reference France pack

E · Macro research complete (pillars · not target-specific)

F · Strategic frame (carries across all DE targets)

  1. No Matching Adjustment in Germany — German life insurers use Volatility Adjustment (Solvency II Art 77d). MA-eligible appetite is UK-anchored; cross-border MA via PRA/EIOPA framework pending PPLX-G output.
  2. MEAG (Munich Re asset manager) is the central node — €12bn→€20bn infrastructure debt scaling · sole arranger track record on €450m DB Regio rolling stock + €300m Spain hybrid + Portugal Margalha solar. Approach as deal-flow partner, not pitch.
  3. AllianzGI VBL €500m mandate (Aug 2025) = scale proof for European institutional infra debt allocation.
  4. EUR/GBP hedge cost 0–15bps annualised — does not kill GBP investment economics for EUR insurers given UK rate premium ~170bps.
  5. 15–30yr senior fixed EUR bilateral = SONG innovation slot · structurally vacant in DE 2024-26 market (banks max 24yr LBBW only · public bonds max 15yr · insurer bilaterals max 15yr ERGO/Vonovia precedent).
  6. ERGO/Vonovia 15yr secured bilateral ×2 (2024) = most important structural template · same-insurer-same-structure · SONG mirrors at extended tenor.
  7. AnlV 8th Amendment (7 Feb 2025) = 5% infrastructure quota tailwind · estimated €5-10bn fresh Pensionskassen capital unlocked for infrastructure.
Provenance: Audit compiled 8 May 2026 from SONG_DealFinder_Master/03_research/germany/ (10 files including Deep Market Pack + MEGA-8) · FORMAL_SCORES_Batch1-5_Apr2026.md (22 DE-coded rows) · country_strategy_packs_Apr2026/germany/ (5 files) · 02_deal_sheets/germany/ (10 deal sheets dated Mar 2026, pre-v1.3 template, refresh pending) · bpa_market/Germany_Quadoro_Targets_Apr2026.md. Coverage Registry entry #21 Germany = DONE 2026-04. Material findings integrated to v1.2 dashboards 8 May 2026.
Grand Canal Capital Partners · SONG DealFinder · Schön Klinik SE & Co. KG
DF-05 Fossil Transition · Session 26 · 21 Apr 2026 · [AI-Draft] v1.3
Verified via Perplexity Model Council (3 models, 6 batches, 47 claims) · 21 Apr 2026 + CRO/Web governance sweep 23 Apr 2026
24 Verified · 22 Corrected · 1 Disputed · 0 Unverified · 8 primary-source overrides · Confidential — named partner sign-off required before external use